5-Fluor-1-(tetrahydro-2-furyl)uracil

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P301+P310：BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

Tegafur Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R23/24/25:Giftig beim Einatmen, Verschlucken und Berührung mit der Haut.

• S-Sätze Betriebsanweisung:

  S22:Staub nicht einatmen.
  S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
  S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).

• Beschreibung

  Tegafur is an orally bioavailable prodrug form of 5-fluorouracil (5-FU; ). It is converted to 5-FU in vivo enzymatically or by cytochrome P450 oxidation. Tegafur inhibits proliferation of HT-29, BxPC-3, and Panc02 cells (IC₅₀s = 201, 172, and 179 μM, respectively). It also reduces tumor growth in an HT-27 colon carcinoma mouse xenograft model when administered at a dose of 50 mg/kg and in a 4-1ST gastric carcinoma mouse xenograft model when used in combination with uracil. Formulations containing tegafur, in combination with uracil, have been used in the treatment of cancer.

• Chemische Eigenschaften

  White Crystalline Powder

• Originator

  Futraful,Taiho,Japan,1974

• Verwenden

  Isotope labelled Tegafur (T013900), used as an antineoplastic.

• Definition

  ChEBI: Tegafur is an organohalogen compound and a member of pyrimidines.

• Manufacturing Process

  One process from US Patent 4,107,162: 27.4 g of 2,4-bis(trimethylsilyl)-5- fluorouracil and 7.7 g of 2,3-dihydrofuran are dissolved in 70 ml of acetonitrile, and 30 ml of an acetonitrile solution containing 1.3 g of anhydrous stannic chloride are added thereinto with cooling and stirring. 50 ml of acetonitrile containing 1.3 ml of water dissolved therein are then dropwise added over 15 minutes. After return to room temperature, the reaction is further effected with stirring at 40°C for 5 hours. The reaction mixture is neutralized by adding 1 N aqueous ammonia with cooling and stirring (conversion 83%). After the nondissolved substances are removed by filtration, the filtrate is concentrated and dried under reduced pressure. 100 ml of water and 300 ml of dichloromethane are added to the residue to completely dissolve the residue by stirring. The obtained dichloromethane layer is separated. The water layer is subjected to extraction twice with dichloromethane. The thus obtained extracts are combined with the separated dichloromethane layer and the combined extracts, after drying with anhydrous magnesium sulfate, are concentrated and dried. The obtained residue is dissolved in ethanol, and the nondissolved substances are removed by filtration. The filtrate is subjected to recrystallization to give white crystals, followed by further recrystallization of the mother liquor. There are totally obtained 15.6 g of N1-(2'-furanidyl)-5-fluorouracil.Yield: 78% of theory, with respect to 2,4-bis(trimethylsilyl)-5-fluorouracil.
  An alternative process from US Patent 3,635,946: A vigorously stirred reaction mixture consisting of 32.87 g (0.1 mol) of 5-fluorouracilmercury, 100 ml of dimethylformamide and 50 ml of toluene is dried by azeotropic distillation of toluene. It is then cooled to -40°C in a stream of dry nitrogen, and a solution of 21.3 g (0.2 mol) of 2-chlorofuranidin in 20 ml of dried dimethylformamide is gradually added to the stirred mixture, the temperature being maintained between -40°C and -30°C. After completion of the reaction (which is marked by complete dissolution of the starting 5-fluorouracilmercury) i.e. after about 3 to 4 hours, 60 to 80 ml of the solvent are distilled off in vacuo at a bath temperature not exceeding 35°C. 50 to 70 ml of dry acetone are then added and also vacuum distilled. The residue is easily crystallized. It is collected, washed three times with small quantities of ethanol - 10 ml each - and airdried. 12.2 g of N1-(2'-furanidyl)-5-fluorouracil are obtained in the form of white crystalline solids; melting point 160°C to 162°C. Additional treatment of the mother liquor yields 3.0 g more of the product. Yield: 75% of theory, based on the starting 5-fluorouracilmercury.
  After recrystallization from ethanol, 14.3 g of N1-(2'-furanidyl)-5- fluorouracilare obtained, MP 164°C to 165°C.

• Therapeutic Function

  Antineoplastic

• Biochem/physiol Actions

  Tegafur is a pro-drug of 5-fluorouracil, an antimetabolite used as an antineoplastic agent. It has been used as adjuvant chemotherapy for curatively resected colorectal cancer therapy.

• Sicherheitsprofil

  Poison by ingestion. Moderately toxic to humans by intravenous route. Moderately toxic experimentally by intraperitoneal, intravenous, and subcutaneous routes. Experimental teratogenic data. Human systemic effects: nausea and vomiting. Experimental reproductive effects. Questionable human carcinogen producing gastrointestinal tumors. Human mutation data reported. Used as an anti-cancer agent. When heated to decomposition it emits very toxic fumes of Fand NOx.

Tegafur Upstream-Materialien And Downstream Produkte

5-Fluor-1-(tetrahydro-2-furyl)uracil Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(403)Suppliers

17902-23-7, Tegafur Verwandte Suche: